AUSTIN, TX / ACCESS Newswire / August 5, 2026 / T·TIME Health Inc., a Texas-based men's telehealth company, has launched OVERTIME, a physician-prescribed erectile dysfunction treatment designed around transparent pricing instead of hidden fees.
While many online ED services advertise low starting prices, patients often discover additional physician fees, membership charges, platform costs, shipping fees, or other mandatory expenses before they can actually receive treatment. In many cases, the advertised price does not reflect the total cost of care.
T·TIME's model is different. Every OVERTIME subscription includes the physician evaluation (if approved), prescription, compounded medication, ongoing medical oversight, and discreet delivery for one transparent monthly price. There are no membership fees, no physician fees, and no surprise add-on charges after checkout.
OVERTIME combines 12 mg of vardenafil and 12 mg of tadalafil in a single grape-flavored, physician-prescribed dissolvable troche that is placed between the cheek and gum. Patients can choose between a 36-troche Best Value plan, bringing the cost below $6 per dose, or a 12-troche Trial plan for those who prefer to start with a smaller quantity.
This transparent pricing philosophy extends across the entire T·TIME platform. In addition to OVERTIME, T·TIME Health Inc. offers physician-supervised treatments including Enclomiphene 12.5 mg and 25 mg for testosterone optimization, Enclomiphene + Tadalafil medicated gum, Low-Dose Naltrexone (LDN), and Sermorelin ODT (orally disintegrating tablets).
One of T·TIME's most distinctive policies is its approach to Enclomiphene dosing. If a physician determines that a patient is an appropriate candidate for 25 mg Enclomiphene based on blood work, treatment history, or ongoing clinical evaluation, the higher strength is provided at the same subscription price. Patients are never charged more simply because their physician recommends a different dose, and subscription pricing does not increase after enrollment.
"We believe healthcare pricing should be predictable," said Moshe Saraf, Founder of T·TIME. "If a physician changes your dose because it's medically appropriate, your monthly price shouldn't change. Patients should know exactly what they'll pay before they begin treatment, without hidden fees or surprise upgrades."
By combining physician-supervised care, transparent pricing, and flat-rate treatment plans, T·TIME aims to make men's health care easier to understand while removing many of the pricing practices that have become common across the online telehealth industry.
The problem with low advertised ED prices
The online erectile dysfunction market is crowded with offers starting at a few dollars per dose.
But those numbers do not always represent the patient's final cost.
Some programs advertise the price of a generic tablet while charging separately for medical consultations, subscriptions, recurring platform access, shipping, or premium formulations. Other offers require patients to purchase dozens of doses at once to qualify for the advertised price.
According to Saraf, this makes meaningful comparisons difficult.
"A $3 tablet inside a program with a membership fee is not really a $3 treatment," he says. "The only number that matters is what the patient actually pays to complete the process and receive the medication."
T·TIME designed OVERTIME around a simple all-inclusive care plan.
A patient completes an online medical intake. A licensed U.S. physician reviews the information and determines whether treatment is medically appropriate. If approved, the prescription is prepared by a licensed compounding pharmacy and shipped discreetly to the patient.
If the physician does not approve treatment, the patient is refunded.
Two active ingredients instead of one
Most standard erectile dysfunction medications rely on a single PDE5 inhibitor.
OVERTIME combines two: vardenafil and tadalafil.
Vardenafil is the active ingredient associated with Levitra®, while tadalafil is the active ingredient associated with Cialis®.
Both medications work by supporting blood flow during sexual stimulation, but they are commonly associated with different timing characteristics. Vardenafil is generally used for its relatively fast onset, while tadalafil is known for remaining active for a longer period.
T·TIME's goal was to create one treatment that supports both priorities.
"Men generally want two things from ED treatment," Saraf says. "They want it to work when they need it, and they do not want to spend the entire evening watching the clock."
The compounded formula is delivered as a troche rather than a conventional swallowed tablet.
The troche is placed between the cheek and gum and allowed to dissolve slowly. T·TIME instructs patients to use it as prescribed, generally about one hour before sexual activity, with a maximum of one troche within 24 hours.
OVERTIME still requires sexual stimulation to work. It is not an aphrodisiac and does not produce an automatic erection.
Why T·TIME chose a troche
The company says the format was selected to reduce another common source of friction: swallowing pills and waiting for them to pass through the digestive system.
A troche can be taken discreetly and does not require swallowing a conventional tablet.
"This is not about creating a novelty product," Saraf says. "It is about making the treatment easier to take while combining two established active ingredients in one physician-prescribed dose."
Each prescription is compounded according to the physician's instructions by a licensed U.S. pharmacy.
Compounded medications are not FDA-approved, and treatment is available only following an individual medical review.
A trial option without a large commitment
Many ED providers achieve their lowest advertised price by requiring patients to order a large quantity.
T·TIME wanted to give patients a lower-commitment entry point.
The company's trial plan provides twelve troches as a one-month supply for $99, or $8.25 per dose.
Patients who expect to use treatment more regularly can select the 36-troche plan for $69 per month ($207 for 3 months), reducing the cost to $5.75 per dose.
Both plans renew automatically, and patients can cancel future shipments before the next medication is dispensed.
"You should not need to order 30 or 60 doses to find out whether a treatment works for you," Saraf says. "Six doses is enough for many patients to evaluate the experience without making a large upfront commitment."
Removing costs that do not improve treatment
T·TIME previously applied the same operational strategy to hormone-related treatments, including enclomiphene and sermorelin.
Rather than building programs around coaching packages, elaborate presentation, concierge memberships, or premium packaging, the company concentrates spending on physician review, pharmacy preparation, medication, fulfillment, and support.
Saraf argues that a significant portion of telehealth pricing is driven by the operating system surrounding the medication rather than the medication itself.
"Every extra department, manual process, subscription layer, and repeated administrative step eventually appears in the patient's price," he says.
T·TIME attempts to reduce those costs through automated eligibility workflows, integrated patient communication, simplified subscriptions, consolidated support operations, and direct pharmacy coordination.
The company also avoids elaborate packaging.
"The patient is buying treatment, not an unboxing video," Saraf says. "A more expensive box does not improve the prescription."
Automation instead of administrative layers
T·TIME says automation is central to maintaining lower prices.
Medical decisions remain with licensed physicians, while software is used for nonclinical tasks such as intake routing, reminders, eligibility workflows, subscription management, order tracking, and refunds.
Patients who are not approved for treatment receive a refund rather than being forced through a lengthy manual support process.
The company believes this distinction is important.
Automation should reduce administrative work, not replace medical judgment.
"The physician should spend time reviewing the patient," Saraf says. "The physician should not spend time moving information between systems or performing tasks that software can complete safely."
ED treatment without the clinic experience
Erectile dysfunction is common, but many men delay treatment because they do not want to discuss it in person or navigate a traditional clinic.
T·TIME built the OVERTIME process to take place remotely.
Patients complete the intake online, receive physician review, and have approved medication delivered in plain packaging.
There are no waiting rooms and no required in-person clinic visit for patients who can be evaluated through the telehealth process.
The company says privacy is not simply a marketing benefit. It can determine whether someone seeks treatment at all.
"A large number of men know treatment exists but continue putting it off," Saraf says. "Reducing embarrassment and administrative friction makes it easier for them to address the issue properly."
Medical review remains essential
T·TIME emphasizes that OVERTIME is a prescription medication, not a supplement.
It is not appropriate for everyone.
PDE5 inhibitors must never be combined with nitrate medications, which are commonly prescribed for chest pain, because the combination can cause a dangerous reduction in blood pressure.
Patients must disclose their medications, cardiovascular history, and relevant medical conditions during the intake process. The reviewing physician determines whether treatment is appropriate.
Potential side effects can include headache, flushing, nasal congestion, indigestion, back discomfort, and muscle aches.
Patients should seek emergency care for an erection lasting more than four hours or for sudden changes in vision or hearing.
"The objective is not to remove medical oversight," Saraf says. "It is to remove the unnecessary work and expense surrounding that oversight."
Competing through price transparency
Saraf believes online healthcare companies should compete based on the patient's actual cost rather than an artificially low headline price.
For OVERTIME, that means publicly stating the formula, quantity, monthly price, price per troche, renewal structure, and what the program includes.
The 12-troche plan costs $99 per month ($8.25 per troche).
The 36-troche plan costs $69 per month ($207 in total), renewed quarterly ($5.75 per troche).
Physician review, prescription treatment, medication, and delivery are included.
The renewal price remains the same unless the patient changes plans or the company provides notice of a future pricing change.
"We are not claiming to be the cheapest tablet on the internet," Saraf says. "We are offering a dual-active compounded prescription treatment with the medical process included, at a price patients can understand before they begin."
A broader push toward accessible men's health
OVERTIME is part of T·TIME's broader strategy of offering physician-supervised treatments in categories frequently overlooked by larger telehealth companies.
The company began with hormone-related care and is continuing to add treatments based on patient demand.
Instead of requiring patients to enroll in broad optimization packages, T·TIME plans to offer individual treatment options that can stand on their own.
The company's position is that patients should be able to seek help for a specific problem without purchasing services they did not request.
"Men do not always need another wellness program," Saraf says. "Sometimes they have a specific problem and want a straightforward treatment option."
The broader thesis
T·TIME's underlying argument is that telehealth should make established treatments easier and less expensive to access.
Technology alone does not guarantee that result.
A telehealth company can still reproduce the same overhead, complexity, and unclear billing found in traditional healthcare.
The difference depends on how the company is structured.
"We are not trying to recreate an expensive clinic on a website," Saraf says. "We are trying to build the simplest responsible path between a patient, a physician, a pharmacy, and the treatment."
If the approach succeeds, OVERTIME may put pressure on other ED treatment providers to become clearer about what their advertised prices actually include.
For T·TIME, that pressure is intentional.
"Healthcare pricing will not improve because companies voluntarily decide to earn less," Saraf says. "It improves when someone creates a more efficient model and forces everyone else to respond."
T·TIME is a Texas-based men's health company focused on making physician-supervised treatment more accessible, straightforward, and affordable.
Important Safety Information
OVERTIME is a compounded prescription medication containing vardenafil and tadalafil. Compounded medications are not reviewed or approved by the FDA. Prescription treatment is available only if a licensed physician determines that it is medically appropriate following an individual evaluation.
Do not use OVERTIME with nitrates or "poppers." Combining PDE5 inhibitors with nitrates can cause a dangerous drop in blood pressure. Tell the reviewing physician about all medications and medical conditions. Seek emergency medical care for an erection lasting longer than four hours or for sudden vision or hearing loss. Individual results vary, and no specific result is guaranteed.
Website: https://ttime.men/overtime
Media inquiries: press@ttime.men
SOURCE: T·TIME
View the original press release on ACCESS Newswire